Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Sabeen Mekan"'
Autor:
Mor Moskovitz, Isamu Okamoto, Peng Chen, Jilpa Patel, Sabeen Mekan, M. Catherine Pietanza, Yalin Zhu, Renata Eiras, Marcello Tiseo
Publikováno v:
Cancer Research. 83:CT067-CT067
Background: Sacituzumab govitecan is an antibody-drug conjugate comprising an anti-trophoblast cell-surface antigen 2 (Trop-2) antibody coupled to a potent payload, SN-38, via a proprietary, hydrolysable linker. In heavily pretreated patients with me
Autor:
Peiwen Kuo, Emon Elboudwarej, Lauri Diehl, Jilpa Patel, Sabeen Mekan, Juliane M. Jürgensmeier
Publikováno v:
Cancer Research. 83:4396-4396
Introduction: Non-small cell lung cancer (NSCLC) is a major cause of cancer-related deaths globally with high unmet need. A variety of novel therapeutic strategies are being explored to improve patient outcomes including the use of antibody drug conj
Autor:
Kan Yonemori, Tiffany A. Traina, Yasuaki Sagara, Takahiro Nakayama, Masato Takahashi, Kenichi Inoue, O. P. Sharma, Shigehira Saji, Zhenhao Qi, Akihiko Osaki, Yang Qiu, Sabeen Mekan, Tatsuya Toyama, Hiroshi Onuma, Joyce O'Shaughnessy, Norikazu Masuda, Yutaka Yamamoto, Shunji Takahashi, Ian E. Krop, Hiroji Iwata, Shoichi Ohwada
Publikováno v:
Cancer Research. 81:PD1-09
Introduction: U3-1402 is a novel, investigational ADC directed against HER3, which is widely expressed in breast cancer. Safety and preliminary antitumor activity of U3-1402 was previously reported in this ongoing, phase 1/2 clinical trial (NCT029803
Autor:
Marwan Fakih, Hiroya Taniguchi, Sabine Tejpar, M. Kanai, J. Beck, Katrina S. Pedersen, G. Pudussery, Yali Liu, Zev A. Wainberg, Kanwal Pratap Singh Raghav, Hisato Kawakami, Arndt Vogel, Kensei Yamaguchi, Sabeen Mekan, Takayuki Yoshino, Scott Kopetz, K. Bando, Yang Qiu
Publikováno v:
Annals of Oncology. 32:S111
Autor:
Stéphane Oudard, Benoit Beuselinck, Victoria Neiman, Sabeen Mekan, Frede Donskov, Asim Amin, Philippe Barthélémy, Howard Gurney, David F. McDermott, Christian Kollmannsberger, M. Brent McHenry, Osvaldo Arén Frontera, Ignacio Duran, Camillo Porta, Paul Nathan, Elizabeth R. Plimack, Toni K. Choueiri, Daniel Y.C. Heng, Michael R. Harrison, Raya Leibowitz-Amit, David Pook, Robert J. Motzer, Nizar M. Tannir, Marc-Oliver Grimm, Yoshihiko Tomita, Pamela Salman, Saby George, Sjoukje F. Oosting, Sergio Bracarda, Thomas Powles, CheckMate Investigators, Bruce G. Redman, Viktor Grünwald, Bohuslav Melichar, Bernard Escudier, Hans J. Hammers, Michael A. Carducci, Scott S. Tykodi, Brian I. Rini
Publikováno v:
Lancet Oncol
Lancet Oncology, 20(10), 1370-1385. ELSEVIER SCIENCE INC
Motzer, R J, Rini, B I, McDermott, D F, Arén Frontera, O, Hammers, H J, Carducci, M A, Salman, P, Escudier, B, Beuselinck, B, Amin, A, Porta, C, George, S, Neiman, V, Bracarda, S, Tykodi, S S, Barthélémy, P, Leibowitz-Amit, R, Plimack, E R, Oosting, S F, Redman, B, Melichar, B, Powles, T, Nathan, P, Oudard, S, Pook, D, Choueiri, T K, Donskov, F, Grimm, M O, Gurney, H, Heng, D Y C, Kollmannsberger, C K, Harrison, M R, Tomita, Y, Duran, I, Grünwald, V, McHenry, M B, Mekan, S, Tannir, N M & CheckMate 214 Investigators 2019, ' Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma : extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 20, no. 10, pp. 1370-1385 . https://doi.org/10.1016/S1470-2045(19)30413-9
Lancet Oncology, 20(10), 1370-1385. ELSEVIER SCIENCE INC
Motzer, R J, Rini, B I, McDermott, D F, Arén Frontera, O, Hammers, H J, Carducci, M A, Salman, P, Escudier, B, Beuselinck, B, Amin, A, Porta, C, George, S, Neiman, V, Bracarda, S, Tykodi, S S, Barthélémy, P, Leibowitz-Amit, R, Plimack, E R, Oosting, S F, Redman, B, Melichar, B, Powles, T, Nathan, P, Oudard, S, Pook, D, Choueiri, T K, Donskov, F, Grimm, M O, Gurney, H, Heng, D Y C, Kollmannsberger, C K, Harrison, M R, Tomita, Y, Duran, I, Grünwald, V, McHenry, M B, Mekan, S, Tannir, N M & CheckMate 214 Investigators 2019, ' Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma : extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 20, no. 10, pp. 1370-1385 . https://doi.org/10.1016/S1470-2045(19)30413-9
BACKGROUND: In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab showed superior efficacy over sunitinib in patients with previously untreated intermediate-risk or poor-risk advanced renal cell carcinoma, with a manageable safety pro
Autor:
Cristina Ivanescu, Saby George, Bernard Escudier, Hans J. Hammers, Viktor Grünwald, Sabeen Mekan, Paul Nathan, David Cella, Justin Doan, Brian I. Rini, Marc-Oliver Grimm, Jean Paty, Robert J. Motzer
Publikováno v:
The Lancet. Oncology. 20(2)
In the ongoing phase 3, CheckMate 214 trial, nivolumab plus ipilimumab improved overall survival compared with sunitinib in patients with intermediate or poor risk, previously untreated, advanced renal cell carcinoma. We aimed to assess whether healt
Autor:
Masayuki Kanai, Sabeen Mekan, Takayuki Yoshino, Yali Liu, Scott Kopetz, Hiroya Taniguchi, Kensei Yamaguchi, Sabine Tejpar, Geetha Pudussery, Arndt Vogel, Zev A. Wainberg, Yang Qiu, Kanwal Pratap Singh Raghav
Publikováno v:
Journal of Clinical Oncology. 39:TPS157-TPS157
TPS157 Background: Patritumab deruxtecan (HER3-DXd; U3-1402) is a novel, investigational antibody drug conjugate comprising an anti-HER3 monoclonal antibody, a tetrapeptide-based linker, and a topoisomerase I inhibitor payload. Ongoing clinical trial
Autor:
Shiraj Sen, Sabeen Mekan, Melissa Lynne Johnson, Toshihiko Doi, Manish R. Patel, Yasuyuki Okuda, Sarina Anne Piha-Paul, Ben Cheng, Yusuke Myobatake, Gul Serbest, Toshio Shimizu, Johanna C. Bendell
Publikováno v:
Journal of Clinical Oncology. 38:TPS3646-TPS3646
TPS3646 Background: B7 homologue 3 (B7-H3) is a protein that is overexpressed in various cancer types, including lung, head and neck squamous cell carcinoma, prostate, esophageal, and breast. B7-H3 overexpression is associated with poor prognosis bec
Autor:
Sabeen Mekan, Philippe Barthélémy, Marc-Oliver Grimm, Bohuslav Melichar, Allen C. Chen, Robert E. Hawkins, David F. McDermott, Christian Kollmannsberger, Brian I. Rini, M. Brent McHenry, Megan Wind-Rotolo, Sergio Bracarda, Nizar M. Tannir, Carlos H. Barrios, Toni K. Choueiri, Camillo Porta, Osvaldo Arén Frontera, Bernard Escudier, Robert J. Motzer, Yoshihiko Tomita, Justin Doan, Howard Gurney, V. Neiman, Frede Donskov, Alain Ravaud, Pamela Salman, Hans J. Hammers, Daniel Castellano, Thomas Powles, Saby George, Elizabeth R. Plimack, Padmanee Sharma
Publikováno v:
CheckMate 214 Investigators 2018, ' Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma ', The New England Journal of Medicine, vol. 378, no. 14, pp. 1277-1290 . https://doi.org/10.1056/NEJMoa1712126
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
NEW ENGLAND JOURNAL OF MEDICINE
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
NEW ENGLAND JOURNAL OF MEDICINE
BACKGROUND: Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced rena
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7be20ad4dc575b4b2b082a5f7053e6c4
https://pure.au.dk/portal/da/publications/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renalcell-carcinoma(9d613da7-a490-4e1e-940a-79cc1309b512).html
https://pure.au.dk/portal/da/publications/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renalcell-carcinoma(9d613da7-a490-4e1e-940a-79cc1309b512).html
Autor:
Bernard Escudier, Thomas Powles, Nizar M. Tannir, Viktor Grünwald, Howard Gurney, C. Porta, T.K. Choueri, Hans J. Hammers, M.-O. Grimm, D.Y.C. Heng, Sabeen Mekan, Saby George, M.B. McHenry, Brian I. Rini, Scott S. Tykodi, Robert J. Motzer, David F. McDermott, Christian Kollmannsberger, Michael R. Harrison
Publikováno v:
Progrès en Urologie. 28:624-625
Objectifs Le traitement par N + I a demontre un taux de reponse objective (TRO) ainsi qu’une survie globale (SG) superieurs par rapport au sunitinib chez des patients atteints d’un CCRa a risque intermediaire/defavorable (I/D) selon l’IMDC dans